Oxford Immunotec Enters into Definitive Agreement to Acquire Imugen
OXFORD, United Kingdom and MARLBOROUGH, Mass., 2016-06-23 22:05 CEST (GLOBE NEWSWIRE) -- Oxford Immunotec Global PLC (Nasdaq:OXFD), a global, high-growth diagnostics company focused on developing and commercializing proprietary tests for the management of immune-regulated conditions, today announced it has entered into a definitive agreement to acquire substantially all of the assets of Imugen, Inc., a Massachusetts-based clinical laboratory focused on developing and performing specialized testing for tick-borne diseases, for $22.2 million in an all cash transaction expected to close on July 1, 2016.
Consistent with strategic vision: Imugen’s business fits well with our strategy to focus on immune-regulated conditions. Tick-borne disease fits within our target markets as, if untreated, they can become chronic infections. In addition, like TB, they can prey on those with weakened immune systems. Similar to our current products, Imugen’s tests derive many of their proprietary insights through prosecuting the immune system.
Expands addressable market: The acquisition expands the Company into the attractive tick-borne disease market, which includes Lyme disease, increasing our total addressable market by $400 to $500 million.
Leverages commercial resources: Imugen’s business has a high degree of call point overlap with our current TB business. We intend to leverage our existing sales and marketing infrastructure to increase Imugen’s revenue growth over time.
- Adds laboratory capabilities: Imugen’s Massachusetts laboratory will allow us to offer our T-SPOT®.TB test at a second laboratory, thereby increasing testing capacity, allowing for optimized logistics and providing risk mitigation through service redundancy.
“We are very excited about the acquisition of Imugen. It is a significant step towards achieving our vision of becoming a leader in the field of immune-regulated conditions,” said Dr. Peter Wrighton-Smith, Chief Executive Officer of Oxford Immunotec. “Through this acquisition, we are expanding our total addressable market, growing and diversifying our revenue streams and leveraging our commercial infrastructure while at the same time improving our profitability profile.”
“Imugen’s extensive experience and proprietary tick-borne disease testing capabilities are very complementary to Oxford Immunotec’s portfolio of products and services,” said Victor Berardi, Chief Executive Officer of Imugen. “We are excited to combine our testing capabilities with Oxford’s commercial and R&D resources to grow the Imugen business.”
We expect the acquisition of Imugen to contribute approximately $5.5 million in revenues in the second half of 2016, which when added to our previously communicated revenue guidance raises our expected revenues for calendar 2016 to between $79.5 and $82.5 million.
We expect to have approximately $30 million of cash at the end of 2016, which will give the company cash into the second half of 2018 based on our current operating plan.
Conference Call and Webcast
The Company will host a conference call on June 24, 2016 at 8:00 a.m. Eastern Time to provide more information on this announcement. The call will be concurrently webcast. To listen to the conference call on your telephone, please dial (855) 363-5047 for United States callers and +1 (484) 365-2897 for international callers and reference confirmation code 38072518 approximately ten minutes prior to start time. To access the live webcast with presentation slides or an archived recording, visit the Investor Relations section of Oxford Immunotec's website at www.oxfordimmunotec.com. The replay will be available on the Company's website for approximately 60 days. The presentation slides will also be available for download in the Investor Relations section of the Company’s website on June 24, 2016 at 7:00 a.m. Eastern Time.
About Oxford Immunotec
Oxford Immunotec Global PLC is a global, high-growth diagnostics company focused on developing and commercializing proprietary tests for the management of immune-regulated conditions. The Company's first product is the T-SPOT.TB test, which is used to test for tuberculosis infection. The T-SPOT.TB test has been approved for sale in over 50 countries, including the United States, where it has received pre-market approval from the Food and Drug Administration, Europe, where it has obtained a CE mark, as well as Japan and China. The T-SPOT.CMV test and the T-SPOT.PRT test are the Company's second and third products and part of a series of products intended for the transplantation market. In addition to these three products, the Company has an additional six active development programs, each of which leverages our T cell, B cell and innate immune measuring technology. The Company is headquartered near Oxford, U.K. and in Marlborough, Mass. Additional information can be found at www.oxfordimmunotec.com.
Incorporated in May 1989, Imugen, Inc. is a clinical and research laboratory located in Norwood, MA with over 25 years’ experience in the development and performance of specialized assays for tick-borne infections. Imugen is certified under the Clinical Laboratory Improvement Amendments (CLIA) and accredited by the College of American Pathologists (CAP) and is licensed as a clinical laboratory in Massachusetts, New York, Pennsylvania, Rhode Island and Maryland.
T-SPOT and the Oxford Immunotec logo are trademarks of Oxford Immunotec Ltd.
This release contains forward-looking statements that involve risks and uncertainties, including statements about our anticipated plans, objectives, intentions, the anticipated benefits of the transaction, the effects of the transaction, including effects on future financial and operating results, prospects for sales of our products and other statements that are not historical facts. The forward-looking statements in this release are based on current expectations, assumptions and data available as of the date of this release and are subject to known and unknown risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such statements, including but not limited to: risks related to disruption of management time from ongoing business operations due to the transaction and the integration of Imugen into the Company; the risk that the Company may fail to realize the benefits expected from the transaction; the risk that the integration of Imugen into the Company may not progress as anticipated; the risk that the announcement of the completion of the transaction could have adverse effects on the market price of the Company’s common stock; decisions by regulatory authorities, hospitals and other health care institutions, laboratories, physicians, patients and third party payers that could affect the Company’s business and prospects; as well as our ability to expeditiously and successfully expand our sales and distribution networks. The risks included above are not exhaustive. Other factors that could adversely affect our business and prospects are described under the "Risk Factors" section in our filings with the Securities and Exchange Commission (“SEC”). Our filings are available for free by visiting the investor section of our website, www.oxfordimmunotec.com, or the SEC’s website, www.sec.gov.
Investors should give careful consideration to these risks and uncertainties. Forward-looking statements contained herein are based on current expectations and assumptions and currently available data and are neither predictions nor guarantees of future events or performance. You should not place undue reliance on forward-looking statements contained herein, which speak only as of the date of this release. We do not undertake to update or revise any forward-looking statements after they are made, whether as a result of new information, future events, or otherwise, except as required by applicable law.
For Media Inquiries:
Tel: +44 1235 442796
For Investor Inquiries:
Chief Financial Officer
Tel: +1 (508) 573-9953
Tel: +1 (443) 213-0501
Om Nasdaq GlobeNewswire
One Liberty Plaza - 165 Broadway
NY 10006 New York
+1 212 401 8700http://www.nasdaqomx.com
NASDAQ (NASDAQ: NDAQ) is a leading provider of trading, exchange technology, information and public company services across six continents.
Følg saker fra Nasdaq GlobeNewswire
Registrer deg med din epostadresse under for å få de nyeste sakene fra Nasdaq GlobeNewswire på epost fortløpende. Du kan melde deg av når som helst.
Siste saker fra Nasdaq GlobeNewswire
Hitachi Vantara Continues To Bolster Its Global Leadership Team With New Executive Appointments13.12.2017 15:00 | Pressemelding
SANTA CLARA, Calif., Dec. 13, 2017 (GLOBE NEWSWIRE) -- Hitachi Vantara, a wholly owned subsidiary of Hitachi, Ltd. (TSE:6501), today announced new appointments to its global leadership team: Mark Ablett has been named senior vice president of global go-to-market (GTM) strategy and Daniel Chong has been named senior vice president of Asia Pacific (APAC). Both will report to the company's chief revenue officer, Hans-Peter Klaey. Ablett previously served as Hitachi Vantara's senior vice president (SVP) of APAC, where he helped Hitachi Vantara's APAC theatre to achieve record growth. In his new role, Ablett will be responsible for developing the company's global GTM strategy, partnering with Hitachi Vantara's customers to help them successfully navigate and execute complex digital transformation journeys. Prior to joining Hitachi, Ablett held executive positions with Juniper Networks and SpectraLink, among others. Chong will assume Ablett's former post as SVP of APAC
DTLR Selects ShopperTrak Traffic Insights to Optimize Store Performance13.12.2017 12:11 | Pressemelding
Lifestyle retailer uses ShopperTrak to better understand key metrics and customer insights CHICAGO, Dec. 13, 2017 (GLOBE NEWSWIRE) -- Tyco Retail Solutions today announced that DTLR Inc., a US lifestyle retailer, has selected its ShopperTrak in-store traffic analytics solution, to provide shopper behavior insights across all 107 stores in 12 states and Washington D.C. Following a successful pilot, DTLR deployed the ShopperTrak perimeter analytics solution and related advisory services to position the importance of shopper traffic, conversion, and other key metrics across the organization. ShopperTrak advisory services utilized include store segmentation, peer grouping, goal setting and field-level training to help better understand shopper traffic and how to best leverage the new data insights. "We sought a vendor who could offer perspective on our operational activities and provide tangible ways to optimize in-store performance," said Frank Long, vice president of
Percona Collaborates with AWS on Database Delivery Service13.12.2017 09:02 | Pressemelding
Percona Managed Services to Ensure Customers Running Open Source Databases on AWS Take Optimal Advantage of AWS Resources RALEIGH, N.C., Dec. 13, 2017 (GLOBE NEWSWIRE) -- Percona, the company that delivers enterprise-class MySQL®, MongoDB® and other open source database solutions and services, announced collaboration with Amazon Web Services (AWS) to serve as an AWS Standard Tier Consulting Partner and Amazon Aurora Service Delivery Partner in the AWS Partner Network (APN). Percona provides managed services to support the use of Amazon Elastic Compute Cloud (Amazon EC2), Amazon Relational Database Service (Amazon RDS), and Amazon Aurora on the flexible, scalable, pay-as-you-go AWS. Percona also announced Percona Monitoring and Management 1.5 with improved support for MySQL on Amazon RDS and Amazon Aurora MySQL. Migrating workloads to AWS can be a vital part of improving customer experience, gaining deeper business insights and increasing efficiency. Whether
Upstream Security Revs Up Cloud-Based Cybersecurity for Connected and Autonomous Car Fleets with $9M Series A13.12.2017 09:01 | Pressemelding
CRV Joins Existing Investors to Accelerate Company's Expansion in the U.S. and Europe as Market for Connected Vehicles and Automotive Cybersecurity Expects to Grow 20x HERZLIYA, Israel, Dec. 13, 2017 (GLOBE NEWSWIRE) -- Upstream Security, pioneer of the cloud-based cybersecurity platform for connected cars and autonomous vehicles, today announced the closing of $9 million in Series A funding, led by CRV (Charles River Ventures). The round included expanded investments from Israeli-based Glilot Capital Partners and Maniv Mobility. Following a $2 million seed funding round in June, the company will use the latest investment to expand its R&D program and continue building out its world-class engineering and security research teams, and open marketing and sales offices in the United States and Europe. The company is well-resourced to secure the 60 million connected cars on the road today that include commercial trucks, vans, buses and private vehicles, as well as take advantage of
Percona Monitoring and Management 1.5 Provides Enhanced Cloud Support, Improved Interface13.12.2017 09:00 | Pressemelding
Highlights Include Improved Support for MySQL on Amazon RDS and Amazon Aurora, More Efficient Data Collection, Faster Time to Support Resolution RALEIGH, N.C., Dec. 13, 2017 (GLOBE NEWSWIRE) -- Percona, the company that delivers enterprise-class MySQL®, MongoDB® and other open source database solutions and services, announced Percona Monitoring and Management 1.5, the latest release of the company's free and open source platform for managing and monitoring MySQL® and MongoDB® performance. This new release improves support for MySQL on Amazon Relational Database Service (Amazon RDS) and Amazon Aurora, which simplifies configuration and usage, provides more efficient data collection and delivers faster resolution of Percona Support tickets. Organizations are increasingly choosing to run MySQL on Amazon RDS or use Amazon Aurora and require the same insight into database performance that they have with their on-premises deployments to be successful. Percona Monitoring and Man
Ammo Incorporated Releases STREAK Visual Ammunition12.12.2017 15:00 | Pressemelding
SCOTTSDALE, Ariz., Dec. 12, 2017 (GLOBE NEWSWIRE) -- AMMO, Inc. (OTC:POWW), a technology leader and premier American ammunitions manufacturer, today announced its newest product offering, STREAK Visual Ammunition. AMMO, Inc. holds the exclusive worldwide rights for the incredible patented technology used to make the STREAK products. STREAK is one of the most technologically advanced ammunition to hit the market in decades. "We are beyond excited to bring STREAK Visual Ammunition to the market. Our acquisition of the exclusive rights for the STREAK technology is a game changer for both our company as well as the shooting industry. Once you shoot with STREAK and you can actually see your projectile travel throughout its path, you will be bored by shooting normal ammunition," said AMMO, Inc.'s CEO, Fred Wagenhals. Unlike conventional tracers, STREAK rounds are NOT an incendiary, they don't use burning metals to generate light. Replacing fire-hazard burning metals is a non
I vårt presserom finner du alle våre siste saker, kontaktpersoner, bilder, dokumenter og annen relevant informasjon om oss.Besøk vårt presserom